Kongressthemen Accelerating More Sensitive, Quantitative and Predictive Serological and Imaging Biomarkers to Transform Clinical Development in the CNS.
With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.
